AOAngela Oates

Angela Oates

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Angela Oates has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Swabs versus tissue samples for infected diabetic foot ulcers: the CODIFI2 RCT

    by E Andrea Nelson, Colin C Everett, Henrietta Konwea, Angela Oates, Sarah T Brown, Chris Bojke, Michael Backhouse, Howard Collier, Joanna Dennett, Rachael Gilberts, et al.

    Background: Foot ulcers affecting people with diabetes (diabetic foot ulcers) often become infected, potentially leading to amputation. Suspected diabetic foot ulcer infection is treated with immediate empiric antimicrobials, with wound samples for culture and sensitivity collected to optimise antibiotic therapy. Collecting samples with swabs is easier than obtaining tissue, but this reports fewer pathogens and more contaminants. Compared with standard culture and sensitivity laboratory methods, molecular microbiology identifies more organisms. How these differences affect clinical decisions or outcomes is currently unknown. Objectives: Main study: To determine if taking tissue samples versus swabs from suspected infected diabetic foot ulcer affects ulcer healing, antibiotic prescribing, costs of care and patient safety. Substudy 1: To determine the agreement between microbiology results from culture and sensitivity versus molecular techniques and to assess whether intention of prescribers to change antimicrobials differs based on sampling methods. Substudy 2: A health-economic perspective of the expected application of empiric and/or targeted treatment regimens and the cost consequences of treatment decisions based on substudy 1. Substudy 3: To compare questionnaire response rates for theoretically informed versus standard participant letters. Substudy 4: To explore clinician perspectives on diabetic foot ulcer sampling and processing techniques. Design: Main study: Randomised controlled trial of results of performing tissue sampling versus swabbing of wounds in people with suspected mild or moderate infected diabetic foot ulcer. Individually randomised (allocation concealed), 1 : 1, tissue or swab sampling for suspected diabetic foot ulcer infection. Follow-up is 12–24 months. A priori sample size estimate is 730. Substudy 1: Cross-sectional agreement study of microbiology results from molecular versus culture and sensitivity techniques and virtual clinic. Diabetic foot ulcers sampled for standard microbiology and central laboratory analysis (molecular). Substudy 2: Exploratory cost–consequence analysis of molecular processing and the likelihood of empiric and targeted treatment based on treatment decisions from substudy 1. Substudy 3: Randomised trial of theoretically informed versus standard participant letters. Substudy 4: Qualitative study explored clinicians’ perspectives regarding sampling and processing techniques. Setting and participants: Twenty-one United Kingdom diabetic foot ulcer clinics. Participants with suspected mild or moderate infected diabetic foot ulcers. Main outcome measures: Main study: Time to ulcer healing (primary outcome blinded assessment), proportion of ulcers healed, antibiotic usage, ulcer area reduction at 4 weeks, hospitalisation duration, time to death, quality of life and cost-effectiveness. Substudy 1: Extent of agreement regarding presence or absence of pathogens from standard versus molecular microbiology. Decision to revise antimicrobials based on sampling method. Substudy 2: Modelled costs (from virtual clinic) of antimicrobial change for standard or molecular analysis. Substudy 3: Response rate for questionnaires. Results: The trial was stopped early, after enrolling only 149 participants, due to poor recruitment. Main study: The hazard ratio for wound healing for patients undergoing tissue versus swab sampling was 1.01 (95% confidence interval 0.65 to 1.55). The swab group had both higher quality-adjusted life-years and lower costs across most time points. Substudy 1: Agreement between culture and sensitivity and molecular microbiology was low. A higher proportion of molecular versus culture and sensitivity vignettes led to recommendations to change antimicrobials [difference 20.5% (95% confidence interval 8.9% to 31.1%)]. Substudy 2: The modelled costs of molecular processing versus culture and sensitivity were £120 higher per wound. Substudy 3: Response rates were 14.8% higher at 52 weeks (95% confidence interval −3.2% to 31.2%) using a theoretically informed versus standard cover letter. Substudy 4: Clinicians were not confident about replacing culture and sensitivity with molecular microbiology, as the result reporting was unfamiliar to them. Limitations: The trial was underpowered. Conclusions: Trial recruitment was challenging during the COVID pandemic and its aftermath. While the results leave substantial uncertainty regarding differences in healing between the sampling methods, tissue sampling appeared to be costlier and was associated with lower quality-adjusted life-years than swabbing. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 16/163/04.


  • Open Access

    Concordance of molecular microbiology and conventional culture techniques for infected diabetic foot ulcer management

    by Angela Oates, Sarah T. Brown, Colin C. Everett, Fran Game, Jane E. Nixon, Tim Sloan, Michelle M. Lister, Michael Backhouse, Benjamin A. Lipsky, David Russell, et al.

    Aim: The management of infected diabetic foot ulcers (DFUs) requires balancing the need for timely interventions against the desire for targeted antibiotic therapy, which relies on laboratory results. This study aimed to evaluate concordance between molecular and conventional culture and sensitivity (C&S) methods in identifying bacteria from infected DFUs.Methods: This study was conducted alongside CODIFI2, a Phase III randomised controlled trial comparing tissue sampling with wound swabbing. It assessed C&S and metagenomic 16S rRNA gene sequencing (M16S) in DFUs with suspected mild or moderate infections using both tissue and swab samples.Results: In 145 participants, C&S identified 248 microorganisms across 25 genera including eight anaerobic genera. M16S identified a greater number and diversity of microorganisms, detecting 455 across 40 genera, including 173 anaerobes from 15 distinct genera. No bacterial growth was reported in 25.5% (95% CI: 18.0%–32.3%) of C&S samples, whereas M16S identified at least one organism in all samples. While the observed agreement between methods was high (75%), Cohen's Kappa revealed low concordance overall, except for Pseudomonas spp. and Streptococcus spp. (Kappa ≥ 0.5).Conclusions: M16S detected a broader microbial spectrum, including fastidious anaerobes, but its low concordance with C&S and lack of antibiotic sensitivity data, challenge its suitability as a replacement for C&S in mild or moderate DFU infections. It may offer advantages in infections where increased sensitivity is beneficial, particularly where extended culture approaches are recommended to detect fastidious or low‐abundance organisms. For mild to moderate DFU infections, our findings support continued reliance on conventional C&S testing.


  • Open Access

    CODIFI2: Randomised controlled trial to compare clinical and cost‐effectiveness of swabs versus tissue sampling to inform management of infected diabetic foot ulcers

    by E. Andrea Nelson, Sarah T. Brown, Colin C. Everett, Angela Oates, Michael Backhouse, Howard Collier, Joanna Dennett, Rachael Gilberts, Ben Lipsky, Michelle M. Lister, et al.

    BAims/Hypothesis: CODIFI2 compared wound swabbing and tissue sampling in people with infected diabetic foot ulcers (DFU) to determine the effects on clinical outcomes.Methods: Multicentre, Phase III, prospective, non‐blind, 2‐arm parallel group, randomised controlled trial comparing time to ulcer healing (primary outcome), proportions healed, antimicrobial regimen, ulcer area reduction, hospitalisation duration, and time to death for swab compared to tissue sampling. Allocation was via a central and independent randomisation system, with minimisation by DFU site, number, type, size, location, and duration.Follow‐up was 52–104 weeks, with healing confirmed by a blinded assessor. Samplesize target was 730 participants for 90% power to detect a 12.5% difference in healing at 52 weeks.Results: Between May 2019 and May 2022, 149 participants were recruited (75 Swab, 74 Tissue) from 21 UK sites. The 52‐week cumulative incidence of confirmed healing as the first event was 45.3% (33.5%–56.4%) and 44.6% (33.0–55.6%) for swab vs. tissue. The hazard ratio (HR) for healing for tissue vs. swab was 1.01 (95% CI 0.65–1.55). The median (IQR) days in hospital was 17 (12–39) for swab and 16 (10–32) for tissue. Seventeen swab and 7 tissue participants died during follow‐up, and 18.7% and 24.3% of participants in the swab and tissue groups, respectively, had an amputation.Conclusions/Interpretation: This trial was underpowered to determine whether swab or tissue sampling impacted the rate of healing or time to healing. Clinical prescribing and patient outcomes differed slightly between groups; hence, the clinical benefit of tissue sampling is not established.


  • Open Access

    Cost‐effectiveness of swab versus tissue sampling for infected diabetic foot ulcers from the CODIFI2 randomised controlled trial

    by Chris Bojke, Henrietta Konwea, E. Andrea Nelson, Sarah T. Brown, Colin C. Everett, Angela Oates, Michael Backhouse, Howard Collier, Joanna Dennett, Rachael Gilberts, et al.

    Aims: To compare the cost‐effectiveness of wound swabbing versus tissue sampling for infected diabetic foot ulcers.Methods: This multi‐centre, Phase III, prospective, unblinded, two‐arm parallel group, randomised controlled trial compared clinical (reported elsewhere) and economic outcomes of swab versus tissue sampling over a 52–104 week period.Resource use was logged using case record forms and patient questionnaire at weeks 4, 12, 26, 39, 52 and 104, costed using laboratory and published sources from the UK NHS perspective, at 2021/2022 price‐year. EQ‐5D‐3L questionnaires issued at these time points were used to derive quality‐adjusted life‐years (QALYs).To account for imbalances such as age, a regression‐based approach was used to estimate survival, expected costs and QALYs between the sampling arms. Available case analysis (ACA) and multiple imputation methods were applied for self reported missing data, and ACA for researcher‐collected data (survival, hospitalisations and antibiotic use). Probabilistic sensitivity analysis was used to assess the uncertainty of economic results.Results: We recruited 149 participants (75 swab, 74 tissue) from 21 UK sites, between 07 May 2019 and 28 April 2022 (last follow‐up 28 April 2023). Planned sample size was 730 participants, for 90% power to detect 12.5% difference in healing at 52 weeks, but the trial stopped early due to low recruitment.Expected QALYs in the swab‐sampling arm were greater than in the tissue‐sampling arm at weeks 26, 52 and 104.The cost of tissue sampling was greater than of swabbing when including antibiotics and hospitalisation. Swab sampling participants had higher QALYs and lower costs across weeks 26–52, reducing slightly by week 104.Conclusions: Because of higher costs, lower QALYs and lack of evidence of benefit, potentially due to the trial being underpowered, tissue sampling was dominated by wound swabbing in the cost‐effectiveness analysis.


  • Open Access

    Computational Studies on Selected Macrolides Active against Escherichia coli Combined with the NMR Study of Tylosin A in Deuterated Chloroform

    by Biljana Arsic, Jill Barber, Ana Cikos, Manikandan Kadirvel, Emilija Kostic, Andrew J. McBain, Jelena Milicevic, Angela Oates, Andrew Regan

    Although many antibiotics are active against Gram-positive bacteria, fewer also show activity against Gram-negative bacteria. Here, we present a combination of in silico (electron ion-interaction potential, molecular docking, ADMET), NMR, and microbiological investigations of selected macrolides (14-membered, 15-membered, and 16-membered), aiming to discover the pattern of design for macrolides active against Gram-negative bacteria. Although the conformational studies of 14-membered and 15-membered macrolides are abundant in the literature, 16-membered macrolides, and their most prominent representative tylosin A, have received relatively little research attention. We therefore report the complete 1H and 13C NMR assignment of tylosin A in deuterated chloroform, as well as its 3D solution structure determined through molecular modelling (conformational search) and 2D ROESY NMR. Additionally, due to the degradation of tylosin A in deuterated chloroform, other species were also detected in 1D and 2D NMR spectra. We additionally studied the anti-bacterial activity of tylosin A and B against selected Gram-positive and Gram-negative bacteria.


  • Open Access

    Modelling antisepsis using defined populations of facultative and anaerobic wound pathogens grown in a basally perfused biofilm model

    by Angela Oates, Sharon Lindsay, Hitesh Mistry, Fernando Ortega, Andrew J. McBain

    An in vitro model was developed to assess the effects of topical antimicrobials on taxonomically defined wound biofilms. Biofilms were exposed over seven days to povidone-iodine, silver acetate or polyhexamethylene biguanide (PHMB) at concentrations used in wound dressings. The rank order of tolerance in multi-species biofilms, based on an analysis of the average bacterial counts over time was P. aeruginosa > methicillin-resistant Staphylococcus aureus (MRSA) > B. fragilis > S. pyogenes. The rank order of effectiveness for the antimicrobials in the biofilm model was povidone-iodine > PHMB > silver acetate. None of the test compounds eradicated P. aeruginosa or MRSA from the biofilms although all compounds except silver acetate eliminated S. pyogenes. Antimicrobial effectiveness against bacteria grown in multi-species biofilms did not correlate with planktonic susceptibility. Defined biofilm populations of mixed-species wound pathogens could be maintained in the basal perfusion model, facilitating the efficacy testing of treatments regimens and potential dressings against multi-species biofilms composed of wound isolates.


  • Hyaluronan‐Based Nanohydrogels for Targeting Intracellular S. Aureus in Human Keratinocytes

    by Elita Montanari, Angela Oates, Chiara Di Meo, Josephine Meade, Rugiada Cerrone, Antonio Francioso, Deirdre Devine, Tommasina Coviello, Patrizia Mancini, Luciana Mosca, et al.

    Staphylococcus aureus is one of the most significant human pathogens that is frequently isolated in a wide range of superficial and systemic infections. The ability of S. aureus to invade and survive within host cells such as keratinocytes and host immune cells has been increasingly recognized as a potential factor in persistent infections and treatment failures. The incorporation of antibiotics into hyaluronan‐cholesterol nanohydrogels represents a novel paradigm in the delivery of therapeutic agents against intracellular bacteria. The work presented herein shows that NHs quickly enter human keratinocytes and accumulate into lysosomes. When used for targeting intracellular S. aureus the antimicrobial activity of loaded levofloxacin is enhanced, possibly changing the antibiotic intracellular fate from cytosol to lysosome. Indeed, gentamicin, an antibiotic that predominantly accumulates in lysosomes, shows significant and equal antibacterial activity when entrapped into NHs. These results strongly suggest that lysosomal formulations may display preferential activity toward intracellular S. aureus, opening new avenues for the use of HA‐based NHs for treatment of such skin infections.


  • Open Access

    Pursuing Intracellular Pathogens with Hyaluronan. From a ‘Pro-Infection’ Polymer to a Biomaterial for ‘Trojan Horse’ Systems

    by Elita Montanari, Chiara Di Meo, Angela Oates, Tommasina Coviello, Pietro Matricardi

    Hyaluronan (HA) is among the most important bioactive polymers in mammals, playing a key role in a number of biological functions. In the last decades, it has been increasingly studied as a biomaterial for drug delivery systems, thanks to its physico-chemical features and ability to target and enter certain cells. The most important receptor of HA is ‘Cluster of Differentiation 44’ (CD44), a cell surface glycoprotein over-expressed by a number of cancers and heavily involved in HA endocytosis. Moreover, CD44 is highly expressed by keratinocytes, activated macrophages and fibroblasts, all of which can act as ‘reservoirs’ for intracellular pathogens. Interestingly, both CD44 and HA appear to play a key role for the invasion and persistence of such microorganisms within the cells. As such, HA is increasingly recognised as a potential target for nano-carriers development, to pursuit and target intracellular pathogens, acting as a ‘Trojan Horse’. This review describes the biological relationship between HA, CD44 and the entry and survival of a number of pathogens within the cells and the subsequent development of HA-based nano-carriers for enhancing the intracellular activity of antimicrobials.